Zapnometinib: Phase I Clinical Study Results on Safety and Pharmacokinetics

42 participants received single oral doses and 29 participants received daily doses for 7 days in a Phase I clinical trial of zapnometinib. The dataset is a supplementary document describing the safety, tolerability, pharmacokinetics, and pharmacodynamics results from this study, authored by Stephan Stenglein and last updated in April 2026. It includes data from single ascending dose, multiple ascending dose, and drug-drug interaction phases.

Use Cases

• Analyze dose-response relationships based on the single and multiple ascending dose phases described.
• Model pharmacokinetic parameters like Cmax and AUC based on the reported dose-proportional increases.
• Assess drug safety profiles based on the reported treatment-emergent adverse events (TEAEs).
• Study drug-drug and food-drug interactions based on the dedicated interaction phases mentioned.

Strengths

• Data originates from a registered Phase I clinical trial (EudraCT 2021-005225-25).
• Results include specific participant counts for SAD (42) and MAD (29) phases.
• The document reports concrete pharmacokinetic outcomes like dose-proportional Cmax and AUC.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 866.9 KB DOCX file, which is a small, single-document format.

Provenance

Source

figshare

Collection Method

Data was collected from a Phase I, single-center, randomized, double-blind, placebo-controlled trial in healthy adults.

Freshness

Last updated 2026-04-17 05:08:36; freshness should be verified.